Abstract
In order to evaluate the efficacy of interferon alpha (IFNa) in mixed cryoglobulinemia (MC), a prospective multicenter clinical trial was conduced in April 1992. It consisted of treating 20 clinically symptomatic MC patients with IFNa for 26 weeks. Hepatitis C virus (HCV) infection was detected in 16 patients. A complete or partial clinical remission was obtained in 12 patients (60%). Eleven of these 12 responders (91.6%) experienced a clinical relapse less than 12 months after the end of therapy. Side effects were noted in 10 patients (50%). It was concluded that subcutaneously administered IFNa does not provide long-term remission.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Aged
-
Aged, 80 and over
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Chemotherapy, Adjuvant
-
Cryoglobulinemia / complications
-
Cryoglobulinemia / therapy*
-
Female
-
Hepatitis C / complications
-
Hepatitis C / therapy
-
Humans
-
Injections, Subcutaneous
-
Interferon Type I / administration & dosage
-
Interferon Type I / therapeutic use*
-
Male
-
Middle Aged
-
Plasma Exchange
-
Prospective Studies
-
Recombinant Proteins
-
Recurrence
Substances
-
Adrenal Cortex Hormones
-
Antiviral Agents
-
Interferon Type I
-
Recombinant Proteins